Metastatic Hepatocellular Carcinoma in the Esophagus Following Liver Transplantation
Li-Yi Xie,Min Fan,Jia Fan,Jian Wang,Xuan-Li Xu,Guo-Liang Jiang
DOI: https://doi.org/10.1002/lt.21546
2008-01-01
Liver Transplantation
Abstract:We report here a case of post–orthotopic liver transplantation (OLT) hepatocellular carcinoma (HCC) metastasizing to the esophagus. To the best of our knowledge, this is the ninth case of liver carcinoma metastasizing to the esophagus and the first after OLT. A 50-year-old Chinese male presenting with a 5-month history of dysphagia and odynophagia visited our hospital in June 2007. His past medical history included a 30-year history of hepatitis B virus infection and long-term cirrhosis. The patient had undergone a splenectomy for cirrhosis-induced splenomegaly in 1997. In addition, the patient was diagnosed with HCC in 2004, which was a 3-cm lesion in the right lobe of the liver at the time of initial diagnosis. The patient was treated by OLT on July 23, 2004. Pathology of the tumor demonstrated a moderately differentiated HCC in the right lobe with nodular cirrhosis in the liver, and tumor thrombus was found in portal veins. He received 9 cycles of systemic chemotherapy using the regimen of epirubicin (40 mg/day, days 1-3), cisplatin (20 mg/day, d1-3), and 5-flurouracil (0.5 g/day, days 1-3). The patient was treated with tacrolimus after OLT and was recurrence-free until April 2007, when a mass was detected in the right lobe of the transplanted liver by a routine follow-up computed tomography (CT) scan of the abdomen (Fig. 1A). He was clinically diagnosed with recurrent HCC to the liver allograft and received transcatheter arterial chemoembolization with cisplatin and 5-flurouracil. He completed transcatheter arterial chemoembolization without any complications. Follow-up CT of the abdomen revealed radiological partial response. However, the patient developed dysphagia and odynophagia in May 2007, and the symptoms progressed rapidly. The patient was referred to our hospital in June 2007, and a thoracic CT scan was performed, which showed increased thickness in the middle of the thoracic esophageal wall. In addition, multiple subcentimeter (0.3–0.5 cm in diameter) lymph nodes were observed in the mediastinum (Fig. 1B). Esophageal endoscopy revealed a 4-cm-long cauliflower-like neoplasm with necrosis in the anterior wall of the thoracic esophagus 2 cm above the carina (Fig. 2). A biopsy of the esophageal lesion was taken, and the histology was investigated by a pathologist who specialized in HCC and was compared to the original HCC specimen. Histologically, the primary liver tumor was composed predominantly of epithelioid clear cells arranged in large nests or sheets (Fig. 3A,B), and the esophageal lesion demonstrated identical microscopic features (Fig. 3C,D). Immunohistochemically, lesions in both the liver and esophagus were positive for alpha-fetoprotein (AFP) and Hepa (Fig. 4A,B) but negative for cytokeratin 7 and cytokeratin 19. On the basis of the morphologic features and immunohistochemical profile, the esophageal lesion was diagnosed as a metastatic HCC (clear cell variant). Computed tomography scans showed the primary (liver) and metastatic (esophagus) lesions of HCC: (A) a mass in the right lobe of the transplanted liver (arrow) and (B) the thickened mid-esophageal wall (arrow). Endoscopy showed a cauliflower-like neoplasm in the esophagus. Biopsy from the liver and esophagus (hematoxylin and eosin stain) demonstrated the histological similarity of the primary and metastatic tumors: (A) the primary liver tumor (magnification ×100), (B) the primary liver tumor (magnification ×200), (C) the metastatic esophageal tumor (magnification ×40), and (D) the metastatic esophageal tumor (magnification ×400). The esophageal tumor expressed both alpha-fetoprotein and Hepa in immunohistochemistry: (A) expression of alpha-fetoprotein in the esophageal tumor (magnification ×400) and (B) expression of Hepa in the esophageal tumor (magnification ×400). No other metastatic focus could be detected, and the initial recurrence focus in the liver remained stable. The patient was treated with external-beam radiation therapy of the esophageal metastasis to a total dose of 60 Gy in 30 fractions. The gross tumor volume was defined as the volume of the metastatic and nodal tumor mass visualized on CT and barium esophagram, and the planning target volume was defined as the gross tumor volume plus a 3- to 3.5-cm margin in the cranial and caudal direction. Most of the patient's symptoms were relieved after irradiation. At the latest follow-up visit on March 10, 2008 (220 days after the completion of radiation therapy), no evidence of recurrence was detected in the esophagus on endoscopy, and the hepatic lesion was stable on abdominal CT. CT, computed tomography; GI, gastrointestinal; HCC, hepatocellular carcinoma; OLT, orthotopic liver transplantation. The esophagus is an uncommon site of cancer metastasis. For HCC, distant metastasis is a common finding of treatment failure and occurs in 30% to 75% of cases. The most common sites for extrahepatic metastases of HCC are the lungs (46.3%), regional lymph nodes (30.3%), bone (11.2%), intraperitoneal organs (18.5%), and adrenal gland (12.5%). The incidence of gastrointestinal (GI) metastases is infrequent, and esophageal metastasis from HCC is extremely rare. Ihde et al.1 reviewed a series of 67 HCC patients in a 6-year period at the Memorial Sloan Kettering Cancer Center, and only 1 (1.5%) GI metastasis was found. Two studies from Taiwan reported 2% (8/396) and 0.5% (11/2237) rates of GI metastases from HCC, none of which occurred in the esophagus. The first case of liver carcinoma metastasizing to the esophagus was reported by Malenchini and Resano2 in 1953. Twelve years later, Sohn et al.3 reported a second case in detail in JAMA. Our literature search using PubMed revealed 6 more cases from Japan. However, there is no report in the literature for HCC metastasizing to the esophagus after liver transplantation. Although clinically evident esophageal metastasis from HCC is rarely reported, subclinical hematogenous spread to the esophagus is not uncommon. Arakawa et al.4 investigated the walls of the stomach and esophagus in an autopsy series of 55 HCC patients associated with hepatic cirrhosis and found venous tumor thrombi in 12 cases of 31 patients (38.7%) who had distant hematogenous metastases. It is well known that the hemodynamics of liver blood flow are altered in hepatic cirrhosis patients, including portal hypertension and diverted blood flow of the liver parenchyma. Studies have demonstrated that in liver cirrhosis patients there is retrograde portal blood flow formation with portosystemic collateral vessels developed to equalize pressures between the 2 venous systems, and this may be even more likely when the portal vein is occluded from either a bland or tumor thrombus. One such collateral route is related to the esophagus. However, it seems discrepant that only a few cases of esophageal metastasis from HCC have been documented in the literature, whereas HCC is a common cancer in Asia. It is reasonable to postulate that the clinical manifestation of the disease in the esophageal wall from tumor thrombi is not likely to occur, given the short survival time of HCC patients with metastasis. In our case, immunosuppression after OLT may also contribute partly to the occurrence of metastasis in an uncommon site. An increased risk of developing nonhepatic malignant tumors in immunosuppressed patients after liver transplantation is well documented. However, most immunosuppression-induced malignancies are primary. A total of 19 cases of esophageal carcinomas have been reported after liver transplantation; 74% (14/19) of the reported de novo esophageal tumors were squamous cell carcinoma, and 26% (5/19) were adenocarcinoma.5 In conclusion, metastasis of HCC in the esophagus is a rare manifestation after liver transplantation. Radiotherapy can be effective for disease control. Close follow-up of the transplanted liver, as well as secondary sites associated with portal drainage, is important after treatment. We thank Professor Jia-De Lu from the National University Hospital of Singapore for his assistance with the English editing of this case report.